EP3596204A1 - Improved reverse genetics for single strand negative rna viruses - Google Patents
Improved reverse genetics for single strand negative rna virusesInfo
- Publication number
- EP3596204A1 EP3596204A1 EP18706536.2A EP18706536A EP3596204A1 EP 3596204 A1 EP3596204 A1 EP 3596204A1 EP 18706536 A EP18706536 A EP 18706536A EP 3596204 A1 EP3596204 A1 EP 3596204A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- virus
- plasmid
- strain
- plasmids
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
- C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
Definitions
- the present invention relates to an improved reverse genetics system for rescuing negative RNA virus from low virulent virus strains, in particular for an avian paramyxovirus from Avulavirus genus, the Newcastle Disease Virus (NDV) and another paramyxovirus, Peste des Petits Ruminants Virus (PPRV) from Morbillivirus genus.
- NDV Newcastle Disease Virus
- PPRV Peste des Petits Ruminants Virus
- Reverse genetics have been widely used to edit virus genomes and rescue modified viruses with altered functions or new vaccine properties (1 ).
- the general scheme for this method relies on the cloning of the complete viral genome, segmented or not, in one or several plasmids under promoters that will generate negative RNAs.
- Complementary plasmids are produced to express viral proteins that will take over the transcribed viral genome (1 ). Since the transfection of a high number of plasmids of different size into one cell is tricky but indispensable for successful virus rescue, several groups have tried to improve the system either by reducing the number of plasmids to be used (2, 3) or by generating cells that constitutively express the viral polymerase complex. However, the latter is a more complicated and time-consuming process.
- NDV Newcastle Disease Virus
- Avulavirus genus which is an avian Paramyxoviridae from Avulavirus genus, becomes again an animal health priority, at least in the countries where it is highly prevalent (Africa and Asia), because of the progressive reduction of the vaccination efficacy in the field currently ascribed to an antigenic drift of the virus.
- This issue mobilizes researchers in the world to generate improved vaccines (e.g. antigenically closer to circulating viruses) to prevent or treat its propagation.
- Reverse genetics has long been used in research on NDV virulence, vaccine generation, oncolytic applications, virion assembly, etc. (13-16).
- the conventional reverse genetics of NDV involves four different plasmids (13).
- N, P and L genes are cloned into plasmids downstream from polymerase promoters CMV or T7. These plasmids are co-transfected into eukaryotic cells and transcribed directly by the cells under the control of CMV promoter or indirect transfection, by the bacteriophage T7 RNA polymerase (17, 18). Since NDV reverse genetics was first developed in the 1990s, the technology has been extensively used in research (13). For example, virulent factors of the virus have been identified and some gene functions have been clarified (10, 13, 20, 21 ). Different modified vaccine candidates have also been generated (14, 22).
- T7 RNA polymerase (T7pol) transgenic cell lines were generated to replace the use of a recombinant T7pol- fowlpox virus, thus eliminating the risk of contamination of the rescued virus by the fowlpox virus (18).
- T7pol T7 RNA polymerase
- Other authors used an additional plasmid to express T7pol (25).
- the T7pol promoter was replaced by the CMV promoter, which renders the reverse genetics independent of the T7pol, simplifies the molecular constructions and extends the types of cell lines that can be used to rescue the viruses (17).
- Peste desdriven ruminants is a highly contagious viral disease of sheep, goats and wild small ruminants that causes mortality rates that may be as high as 90% in naive populations.
- the disease is caused by a morbillivirus, Peste desdriven ruminants virus (PPRV), which is an enveloped ribonucleic acid (RNA) virus with a monosegmented genome of negative sense, belonging to the genus Morbillivirus in the family Paramyxoviridae.
- PPRV Peste desdriven ruminants virus
- RNA enveloped ribonucleic acid
- MV measles virus
- CDV canine distemper virus
- PDV phocine distemper virus
- CMV cetacean morbilliviruses
- the most widely used vaccine is the PPRV Nigeria 75/1 vaccine strain developed by the CIRAD (Centre de cooperation Internationale en say agronomique pour le developpement) in 1989 in collaboration with the Institute for Animal Health at Pirbright UK. It was produced by attenuating the virulent strain PPRV Nigeria 75/1 through multiple passages in cell cultures. In particular, this virus was isolated originally from a sick goat on primary lamb kidney cell culture in Nigeria and attenuated by serial passages on Vera cells (Diallo et al., 1989). This vaccine is perfectly safe and provides a good protection to animals during their economic life (i.e. at least 3 years). The massive vaccination campaigns planned by the OIE depend on these attenuated vaccines.
- the present invention provides an improved reverse genetics system developed for single strand negative RNA viruses, in particular for an avian paramyxovirus, the Newcastle Disease Virus (NDV) and for another paramyxovirus, Peste des Petits Ruminants Virus (PPRV), in which the number of plasmids was reduced from four to two.
- NDV Newcastle Disease Virus
- PPRV Peste des Petits Ruminants Virus
- the 2-plasmids system enables earlier and increased production of rescued viruses and, in addition, makes it possible to rescue viruses that it was not possible to rescue using the 4-plasmids system.
- the 2-plasmids system developed for NDV reverse genetics not only simplifies the transfection procedure, reduces the number of plasmids to be transfected and requires less time to achieve successful rescue, but also increases the efficiency for lentogenic-type viruses compared to the conventional 4-plasmids system. Using this improvement in reverse genetics for other viruses may be equally successful.
- a first object of the invention is an in vitro method of rescuing negative RNA virus from low virulent virus strain(s) or lentogenic-like virus strain(s), comprising at least the steps of:
- a pGenome plasmid comprising at least a sequence encoding a virus genome from low virulent virus strain(s) or lentogenic-like virus strain(s) and
- a pNPL helper plasmid comprising at least the sequences encoding the structural viral proteins nucleocapsid protein (N), phosphoprotein (P) and large protein (L),
- low virulent virus strain(s) or lentogenic-like virus strain(s) belong to the Paramyxoviridae family.
- the invention also relates to an eukaryotic host cell transformed (transfected) with the two- plasmid system according to the invention.
- Another object of the invention is a rescued negative RNA virus isolated from the eukaryotic cell transformed according to the method as defined above, preferably after 1 day post- transfection, more preferably after 3 days post-transfection.
- the invention also provides a helper plasmid pNPL comprising at least the sequences of the structural viral proteins of a virus belonging to the Paramyxoviridae family, in particular the Newcastle Disease Virus (NDV) or the Peste des Petits Ruminants Virus (PPRV), consisting of nucleocapsid protein (N), phosphoprotein (P) and large protein (L), under control of a promoter, in particular a CMV promoter.
- NDV Newcastle Disease Virus
- PPRV Peste des Petits Ruminants Virus
- Another object of the invention is a kit for in vitro direct rescue of negative RNA virus from low virulent virus strain(s) or lentogenic-like virus strain(s) comprising at least:
- a pGenome plasmid comprising at least a sequence encoding the virus genome from low virulent virus strain(s) or lentogenic-like virus strain(s), preferably belonging to the Paramyxoviridae family, in particular the Newcastle Disease Virus (NDV) or the Peste des Petits Ruminants Virus (PPRV),
- a pNPL helper plasmid comprising at least the sequences of the structural viral proteins of a negative RNA virus, preferably belonging to the Paramyxoviridae family, in particular the Newcastle Disease Virus (NDV) or the Peste des Petits Ruminants Virus (PPRV), consisting of nucleocapsid protein (N), phosphoprotein (P) and large protein (L),
- the in vitro method of rescuing negative RNA virus from low virulent virus strain(s) or lentogenic-like virus strain(s) according to the invention comprises at least the steps of:
- a pGenome plasmid comprising at least a sequence encoding the virus genome from low virulent virus strain(s) or lentogenic-like virus strain(s) and
- a pNPL helper plasmid comprising at least the sequences encoding the structural viral proteins nucleocapsid protein (N), phosphoprotein (P) and large protein (L),
- either the pGenome plasmid comprises a sequence encoding a virus genome which is partially deleted or mutated, and the host cell is optionally modified for expressing the said deleted gene(s),
- pNPL helper plasmid is substituted by a helper plasmid comprising one or two sequences selected from the group consisting of sequences encoding N, P and L proteins, and the host cell is modified to complement the expression of missing protein(s).
- low virulent virus strain(s) or lentogenic-like virus strain(s) belong to the Paramyxoviridae family.
- the co-transfecting technologies for step (i) and culturing conditions for step (ii) are well known from the man skilled in the art.
- the term 'rescuing a virus' according to the invention encompasses any process well known from the man skilled in the art allowing the generation of an infectious viral clone from a cDNA of the virus genome.
- RNA virus' encompasses negative-sense single-stranded RNA viruses that require a RNA replicase, also known as RNA-dependent RNA polymerase (RdRp), to initiate replication of their genome.
- RNA replicase also known as RNA-dependent RNA polymerase (RdRp)
- Such viruses belong to the order Mononegavirales including Bornaviridae, Filoviridae, Mymonaviridae, Nyamiviridae, Paramyxoviridae, Pneumoviridae, Rhabdoviridae families.
- such viruses all comprise sequences encoding N, P and L proteins and belong to Bornaviridae, Filoviridae, Mymonaviridae, Nyamiviridae, Paramyxoviridae, Pneumoviridae, or Rhabdoviridae families.
- negative RNA virus is a paramyxovirus, preferably an avian paramyxovirus, and more preferably the Newcastle Disease Virus (NDV).
- NDV Newcastle Disease Virus
- negative RNA virus is a paramyxovirus from Morbillivirus genus, and more preferably Peste des Petits Ruminants Virus (PPRV).
- the term 'low virulent virus strains or lentogenic-like virus strains' according to the invention encompasses live or recombinant attenuated viruses in the target species.
- Such 'low virulent virus strains or lentogenic-like virus strains' have a reduced pathogenic phenotype compared to the virulent virus strains of the same genus.
- a reduced pathogenic phenotype encompasses a reduced infection capacity and/or a reduced replication capacity, and/or a reduced and/or restricted tissue tropism, and/or a default or defect in the assembly of the viral particles, more particularly a reduced infection capacity.
- a low virulent virus strain is the PPRV Nigeria 75/1 vaccine strain disclosed in Diallo et al., 1989 (Genbank accession number KY628761.1 or X74443.2, 15948 bp linear RNA, SEQ ID NO: 31 ).
- the invention relates to an in vitro method of rescuing negative RNA virus wherein the low virulent virus strain is selected from PPRV Nigeria 75/1 strain (SEQ ID N0:31 ) or PPRV recombinant Nigeria 75/1 strain.
- a low virulent virus strain is the NDV LaSota strain (Genbank accession numbers AY845400.2, AF077761 or JF950510, 15186 bp linear RNA, SEQ ID NO: 12).
- NDV LaSota strain Genbank accession numbers AY845400.2, AF077761 or JF950510, 15186 bp linear RNA, SEQ ID NO: 12.
- the molecular basis for the different level of pathogenicity is known to be linked to the sequence of the cleavage site of the precursor of the fusion protein F.
- a pathogenic NDV strain for example has at least one extra pair of basic amino-acids motif 2X-R-X-R/K-R-F 7 and can be cleaved by a wide range of proteases of the furin family in different host cells.
- virulence is not determined by a single genetic element. In contrast, several mutations accumulated in the leader, trailer and viral proteins have been shown to support virulence for Measles, rinderpest and canine distemper viruses. Genetic determinisms of PPRV virulence are even less characterized.
- the low virulent or lentogenic virus strains for avian paramyxovirus have a genotype coding for a F protein cleavage site which has less than 4 basic amino acids, in particular less than 3 basic amino acids, and preferably only two basic amino acids, for example in amino acids positions 1 12-1 17 for NDV virus. It is also said that the F protein cleavage site is modified or mutated (Fmu).
- the low virulent virus strain is selected from the group consisting of virus strains having a genotype with a lentogenic-like F protein cleavage site, in particular NDV LaSota strain (SEQ ID N0: 12), or NDV recombinant strains such as LaSota recombinant strain (LaSota/M-Fmu SEQ ID NO: 14), or attenuated recombinant MG-725 strain (MG- 725/Fmu SEQ ID NO: 9).
- NDV LaSota strain SEQ ID N0: 12
- NDV recombinant strains such as LaSota recombinant strain (LaSota/M-Fmu SEQ ID NO: 14), or attenuated recombinant MG-725 strain (MG- 725/Fmu SEQ ID NO: 9).
- the invention relates to an in vitro method of rescuing negative RNA virus, wherein the low virulent virus strain is selected from NDV LaSota strain (SEQ ID N0: 12) or NDV recombinant LaSota strain.
- the term 'genotype with a lentogenic-like F protein cleavage site' encompasses genotype wherein the amino-acid positions 1 12-1 17 of the precursor of the F protein contain less than 4 basic amino acids, in particular less than 3 basic amino acids, and preferably only two basic amino acids.
- the velogenic strains have five basic amino acids, while the lentogenic strains have two basic amino acids (Fig. 3). This difference makes the F protein of virulent strains more prone to be cleaved by various proteases present in various tissues and the virus is then activated to amplify whereas the F protein of attenuated strains is only cleaved in environments like the digestive and respiratory tracts or in vitro, in cell culture medium containing trypsin.
- the pGenome plasmid comprises at least a sequence encoding the virus genome from low virulent virus strain(s) or lentogenic-like virus strain(s), in particular at least a sequence encoding the genome Newcastle Disease Virus (NDV) from low virulent strain(s) or lentogenic-like virus strain(s), such as LaSota strain.
- NDV Newcastle Disease Virus
- the sequence encoding the virus genome from low virulent virus strains or lentogenic-like virus strains comprises a modified F protein cleavage site, in particular a sequence of formula (I) 2 Xi-X 2 - 3-X4- 5 - 6 7 wherein X 2 and X 5 are independently arginine (R) or lysine (K), preferably arginine (R) and Xi , X 3 , X4, X 6 are independently selected from the group consisting of non-basic amino acids.
- the sequence encoding the virus genome from low virulent virus strains or lentogenic-like virus strains according to the invention comprises a modified F protein cleavage site, in particular a sequence GRQGRL (SEQ ID NO: 18).
- the pGenome plasmid comprises at least a sequence encoding the virus genome of Newcastle Disease Virus (NDV) from a low virulent virus strain, such as LaSota strain (Genbank accession numbers Genbank accession numbers AY845400.2, AF077761 or JF950510, 15186 bp linear RNA, SEQ ID N0: 12).
- NDV Newcastle Disease Virus
- the NDV belongs to the Avulavirus genus in the Paramyxoviridae family (4, 5).
- the genome is composed of a 15 kb negative-sense single-stranded RNA molecule with six coding segments surrounded by the leader and trailer viral polymerase promoters (6-8).
- This genome structure (3'-Leader-N-P-M-F-HN-L-Trailer-5') encodes six structural viral proteins: nucleocapsid protein (N), phosphoprotein (P), matrix protein (M), fusion protein (F), hemagglutinin-neuraminidase (HN), large protein (L), and two nonstructural proteins - V and W proteins, respectively (9, 10).
- N, P and L form the viral polymerase complex replicates and transcribes the viral genome (10).
- These three proteins play a crucial role in virus rescue by reverse genetics (1 1 -13).
- the pGenome plasmid comprises at least a sequence encoding the virus genome from low virulent virus strain(s) of Morbillivirus genus, preferably Peste des Petits Ruminants Virus (PPRV), such as PPRV Nigeria 75/1 strain as illustrated in the examples (SEQ ID N0:31 ).
- PPRV Peste des Petits Ruminants Virus
- the pGenome plasmid comprises at least a sequence encoding a virus genome which is partially deleted and/or mutated and the host cell is optionally modified to complement the said deleted gene(s).
- a “mutation” as used herein refers to a change in nucleic acid relative to a reference sequence (which is preferably a naturally-occurring normal or « wild-type » or « reference » sequence), and includes translocations, deletions, insertions, and substitutions mutations.
- a mutation by "substitution” as used with respect to amino acids refers to the replacement of one amino acid residue by any other amino acid residue, excepted the substituted amino acid residue.
- small amino acid residues are used for substitution in order to limit any effect on the overall protein structure.
- the sequence encoding a virus genome within the pGenome comprises a mutation within the cleavage site of the F protein, to be lentogenic-like as the LaSota strain.
- the pGenome plasmid comprises at least a sequence encoding the virus genome of Newcastle Disease Virus (NDV) from recombinant LaSota strain (Lasota/M-Fmu SEQ ID N0:14).
- NDV Newcastle Disease Virus
- the pGenome plasmid comprises at least a sequence encoding the virus genome of Newcastle Disease Virus (NDV) from recombinant MG-725 strain having a lentogenic-like genotype (MG-725/Fmu SEQ ID N0:9).
- NDV Newcastle Disease Virus
- the pGenome plasmid comprises at least a partial sequence of virus genome of Newcastle Disease Virus (NDV) from low virulent (lentogenic) strain (ex: LaSota) combined with partial sequences from virulent strain (ex: MG-725) mutated within the F protein cleavage site.
- NDV Newcastle Disease Virus
- a « host cell modification » as used herein, refers to any genetic modification of the cell allowing permanent or transient expression of deleted and/or mutated gene(s) to complement the said deleted and/or mutated gene(s) in the rescued virus genome. Modifications include insertional cell genome mutagenesis based on transposons or viruses and cell genome editing by specific nucleases (e.g. TALEN or CRIPR/Cas9) and homologous recombination.
- specific nucleases e.g. TALEN or CRIPR/Cas9
- the helper plasmid pNPL used in the method of the invention comprises at least the sequences of the structural viral proteins of a virus belonging to the Paramyxoviridae family, in particular the Newcastle Disease Virus (NDV) or Peste des Petits Ruminants Virus (PPRV), consisting of nucleocapsid protein (N), phosphoprotein (P) and large protein (L), under control of a promoter, in particular a pCMV promoter.
- the pNPL plasmid comprises three independent expression cassettes under a promoter, in particular pCMV promoter to express N, P, L.
- the pNPL helper plasmid comprises at least the sequences encoding the structural viral proteins nucleocapsid protein (N) (SEQ ID N0: 1 ), phosphoprotein (P) (SEQ ID N0:2) and large protein (L) (SEQ ID N0:3) of the Newcastle Disease Virus.
- N nucleocapsid protein
- P phosphoprotein
- L large protein
- SEQ ID N0:3 large protein of the Newcastle Disease Virus.
- the pNPL helper plasmid comprises the sequence SEQ ID N0:4.
- the pNPL helper plasmid comprises at least the sequences encoding the structural viral proteins nucleocapsid protein (N) (SEQ ID N0:26), phosphoprotein (P) (SEQ ID N0:27) and large protein (L) (SEQ ID N0:28) of PPRV.
- the pNPL helper plasmid is substituted by a helper plasmid comprising one or two sequences selected from the group consisting of sequences encoding N, P and L proteins, and the host cell is modified to complement the expression of missing protein(s).
- helper plasmid comprises the sequences encoding for N and P proteins and the host cell is modified to complement the expression of L protein.
- the weight ratio between the first plasmid pGenome and the helper plasmid pNPL ranges from 9: 1 to 1 :9, and is preferably 1 :1.
- the negative RNA virus is a virus belonging to the Paramyxoviridae family, in particular the Newcastle Disease Virus (NDV) or Peste des Petits Ruminants Virus (PPRV).
- NDV Newcastle Disease Virus
- PPRV Peste des Petits Ruminants Virus
- the host cells are eukaryotic cells, in particular mammal cells, preferably baby hamster kidney cells (BHK-21 ) for NDV.
- mammal cells preferably baby hamster kidney cells (BHK-21 ) for NDV.
- BHK-21 baby hamster kidney cells
- the host cells are transfected with an amount of two-plasmid system ranging from 1 ⁇ g to 20 ⁇ g, in particular from 2 to 20 ⁇ g, and preferably from 3 to 5 ⁇ g (total amount of both plasmids).
- the in vitro method of rescuing negative RNA viruses in host cells additionally comprises a step of virus amplification into chicken embryos. In particular, this additional step is managed between culturing step (ii) and recovering step (iii) of the method.
- NDV the host cells in which the infectious virus clone is generated and their supernatants are collected and injected into 10 day old SPF chicken embryos for virus amplification.
- the in vitro method of rescuing negative RNA virus according to the invention additionally comprises a step of amplification of RNA virus into chicken embryos between steps (ii) and step (iii). And in particular, the host cells transformed (transfected) with the two-plasmid system and their supernatants are collected and injected into 10 day old SPF chicken embryos for virus amplification.
- step (i) The co-transfecting technologies for step (i) and culturing conditions for step (ii) are well known from the man skilled in the art.
- the method of rescuing NDV virus may comprise the following steps:
- pNPL plasmid construction amplification of N, P, L genes of NDV from cDNA by PCR and cloning into a plasmid, between a CMV promoter and polyA sequences; then N, P and L genes with CMV promoter and polyA are amplified from pN, pP, and pL by PCR and then cloned into pCMV plasmid to generate pNPL plasmid;
- CMV promoter and polyA replace T7 promoter and terminator of a pKS plasmid and two ribozymes were inserted between CMV promoter and polyA to be the pCMV plasmid; then with PCR and restriction, the full genome of virus is assembled on pCMV plasmid, between both ribozymes, to get the pCMV-NDV (pGenome);
- BHK-21 cells are seeded on the 6-well plate and cultured at 37°C, 5% C02 for overnight; then 1 ⁇ g pCMV-NDV (pGenome) and 1 ⁇ g pNPL (pNPL plasmid) are transfected by Lipofectamin into BHK-21 cells; 3) optionally amplification of the rescued RNA virus:
- the transfected cells with 200 ⁇ _ supernatants are collected and injected into allantoic cavity of 10-days old chicken embryo. This chicken embryo is incubated at 37°C for 3 days and then put at 4°C for overnight;
- the method of rescuing PPR virus may comprise the following steps:
- pNPL plasmid construction amplification of N, P, L genes of PPRV from cDNA by PCR and cloning into a plasmid, between a CMV promoter and polyA sequences; then N, P and L genes with CMV promoter and polyA are amplified from pN, pP, and pL by PCR and then cloned into pCMV plasmid to generate pNPL plasmid;
- CMV promoter and polyA replace T7 promoter and terminator of a pKS plasmid and two ribozymes were inserted between CMV promoter and polyA to be the pCMV plasmid; then with PCR and restriction, the full genome of virus is assembled on pCMV plasmid, between both ribozymes, to get the pCMV-PPRV (pGenome);
- the present invention also provides a eukaryotic host cell transformed (also named transfected) with the two-plasmid system according to the method as defined above.
- the hots cell may be modified to complement the expression of deleted or missing genes.
- the present invention also provides a rescued negative RNA virus isolated from the eukaryotic cell transformed according to the method as defined above, preferably after 1 day post-transfection, more preferably after 3 days post-transfection.
- the present invention also provides a helper plasmid pNPL comprising at least the sequences of the structural viral proteins of a virus belonging to the Paramyxoviridae family, in particular the Newcastle Disease Virus (NDV) or Peste des Petits Ruminants Virus (PPRV), consisting of nucleocapsid protein (N), phosphoprotein (P) and large protein (L), under control of a promoter, in particular a CMV promoter.
- NDV Newcastle Disease Virus
- PPRV Peste des Petits Ruminants Virus
- helper plasmid pNPL of NDV comprises sequences SEQ ID N0:4.
- the pNPL plasmid of NDV comprises three independent expression cassettes under a promoter, in particular pCMV promoter to express N, P, L.
- helper plasmid pNPL of PPRV comprises sequence SEQ ID N0:29.
- the pNPL plasmid of PPRV comprises three independent expression cassettes under a promoter, in particular pCMV promoter to express N, P, L.
- kits comprising, in one or more containers in a single package, a pGenome plasmide and a pNPL helper plasmid as defined above.
- kits according to the present invention further comprise a means for communicating information or instructions, to help using the kits' elements.
- kits for in vitro direct rescue of negative RNA virus from low virulent virus strain or lentogenic-like virus strain comprises at least:
- a pGenome plasmid comprising at least a sequence encoding the virus genome from low virulent virus strain(s) or lentogenic-like virus strain(s), preferably belonging to the Paramyxoviridae family, in particular the Newcastle Disease Virus (NDV) or Peste des Petits Ruminants Virus (PPRV), and/or
- a pNPL helper plasmid comprising at least the sequences of the structural viral proteins of a negative RNA virus, preferably belonging to the Paramyxoviridae family, in particular the Newcastle Disease Virus (NDV) or Peste des Petits Ruminants Virus (PPRV), consisting of nucleocapsid protein (N), phosphoprotein (P) and large protein (L),
- kits for in vitro direct rescue of negative RNA virus from low virulent virus strain or lentogenic-like virus strain comprises at least:
- a pGenome plasmid comprising at least a sequence encoding the virus genome from low virulent virus strain(s) or lentogenic-like virus strain(s) of the Newcastle Disease Virus (NDV) or Peste des Petits Ruminants Virus (PPRV), and/or (ii) a pNPL helper plasmid comprising at least the sequences of the structural viral proteins of the Newcastle Disease Virus (NDV) or Peste des Petits Ruminants Virus (PPRV), consisting of nucleocapsid protein (N), phosphoprotein (P) and large protein (L),
- either the pGenome plasmid comprises a sequence encoding a virus genome which is partially deleted or mutated, and the host cell is optionally modified for expressing the said deleted gene(s),
- pNPL helper plasmid is substituted by a helper plasmid comprising one or two sequences selected from the group consisting of sequences encoding N, P and L proteins, and the host cell is modified to complement the expression of missing protein(s).
- the pGenome and pNPL helper plasmid are provided in the same kit. In another particular embodiment, the pGenome and pNPL helper plasmid are provided in separated kits.
- the present invention provides an improved reverse genetics system for negative RNA viruses allowing increased rescue of low virulent or attenuated virus.
- pN, pP and pL plasmids include N, P and L gene from MG-725 strain, respectively.
- D In the pNPL plasmid, three expression cassettes consisting of pCMV and polyA tail flanking the N, P or L gene from MG- 725 were cloned into the same pCMV vector engineered from a pKS plasmid (see Material and Methods).
- E Downstream, the pMini-genome plasmid includes the promoter pCMV, the leader and trailer of MG-725 flanking the EGFP gene placed in antisense direction.
- F Complete genomes of NDV were assembled by RT-PCR and restriction enzymes into pCMV vector, between the two ribozymes.
- FIG. 1 Mini-genome assay with the 4-plasmids system.
- A Fluorescence appeared after transfection of BHK21 with the mini-genome expressing EGFP and pN, pP and pL.
- B Fluorescence did not appear when pL was not included in the plasmid cocktail used for transfection. Pictures were taken two days after transfection at 10 ⁇ magnification.
- C Optimization of the 4-plasmids system. Histograms show the average and bars are the SD of the number of cells expressing EGFP in triplicate wells(s) of 24-well plates in the same assay.
- Figure 3 Alignment of F protein cleavage sites from the rescued strains in this study and in other strains retrieved from GenBank (SEQ ID N0:19 to SEQ ID N0:25). Multiple alignments performed using the Clustal W method in the DNA star software. The different amino acids in the low-virulent, virulent and rescued strains in the region encompassing residues 1 10-120 are framed. The vertical arrow indicates the trypsin cleavage site.
- Figure 4. Rescue efficiency of the 4-plasmids system. (A) Three days after transfection, viruses were recovered and passaged in eggs for three days then tested by qRT-PCR as detailed in 'Materials and Methods'.
- the pMG-725/Fmu plasmid and H 2 0 were used as positive and negative controls of the qRT-PCR. Only two attenuated strains (LaSota/M Fmu and LaSota/Cherry) were not rescued. (B) Allantoic fluids showing HA and qRT-PCR positive results were considered as successfully rescued (V and L stand for strains with velogenic-like and lentogenic-like F protein cleavage site, respectively). All three velogenic strains (100%) were rescued, versus 6 out 8 lentogenic strains (75%).
- C to F Three days after transfection with pMG-725/EGFP (C), pMG-725/Cherry (D), pMG-725/Fmu/EGFP (E) and pMG- 725/Fmu/Cherry (F), cells were observed under a fluorescent microscope at magnification 10x.
- the two velogenic strains (C and D) show a clear enhancement of the green-fluorescent cells compared to the lentogenic strains (E and F).
- FIG. 5 Optimization of the 2-plasmids system on EGFP mini-genome assay and comparison with the 4-plasmids assay.
- A The 2-plasmids system was optimized by changing the quantitative ratio of pMini-genome and pNPL from 9: 1 to 1 :9 as shown on the X- axis. EGFP positive cells were then enumerated under a fluorescent microscope at magnification 5 ⁇ , in 10 fields of one well of 6-well plates.
- B and C Comparative EGFP mini- genome performance between the 4- and 2-plasmids systems. The pictures were taken 2 days after transfection and suggest a higher number of fluorescent cells with the 2-plasmids systems (Magnification, 5 ⁇ ).
- Baby hamster kidney BHK-21 cells were grown in Eagle's minimum essential medium (Gibco) with 10% fetal bovine serum (PAN-Biotch) and cultured at 37 °C with 5% C0 2 .
- Chemically competent cells, 10-beta strains were purchased from New England Biolabs (NEB).
- NDV chicken/Madagascar/2008 (MG-725) strain isolated from chicken in Madagascar (19), was amplified in 10 day-old specific pathogen free (SPF) chicken embryos (Couvoir de Cerveloup, France). After two days of infection, allantoic liquid was harvested and stored at -80 °C.
- NDV LaSota strain (Genbank accession numbers AY845400.2, AF077761 or JF950510, 15186 bp linear RNA, SEQ ID NO: 12), kindly provided by ISZVe, Italy, was amplified and stored in the same way as the MG-725 strain.
- PPRV from Nigeria 75/1 attenuated vaccine strain was isolated originally from a sick goat on primary lamb kidney cell culture in Nigeria and attenuated by serial passages on Vero cells (Diallo et al. , 1989) (Genbank accession number KY628761 .1 or X74443.2, 15948 bp linear RNA, SEQ I D NO: 31 ).
- RNA of MG-725 was extracted using the NucleoSpin RNA virus kit (MACHEREY-NAGEL) according to the manufacturer's instructions. RNA was used to generate cDNA with the Super Script HI First-Stand kit (Invitrogen). Pfu Ultra Fusion HS DNA polymerase (Agilent) was used to amplify the N, P and L genes of MG-725 from cDNA and the three genes were cloned into the pCI-neo plasmid by restriction enzymes (NEB) (see Table 1 , Fig.1 A to C).
- NEB restriction enzymes
- a F protein cleavage sites are 2 RRRRRF 117 .
- F protein cleavage sites are 2 GRQGRL 117 .
- the T7 RNA polymerase promoter and terminator of pKS plasmid were replaced by the CMV promoter and polyA from pCI-neo.
- the two ribozymes were then inserted between the CMV promoter and polyA sequences.
- a fragment with multiple cloning sites was introduced between the two ribozymes to obtain a pCMV vector.
- the N, P and L genes of the MG- 725 strain flanked by the CMV promoter and polyA tail were amplified from pN, pP and pL and cloned into the same pCMV vector to generate pNPL plasmid (Fig. 1 D).
- a mini-genome plasmid was also prepared to assess the usefulness of the helper plasmids.
- the enhanced green fluorescence protein (EGFP) gene was flanked by the leader and trailer strains of MG-725 by overlap PCR and then cloned into pCMV vector, between ribozymes, in the reverse direction to get the pMini-genome (Fig. 1 E).
- EGFP enhanced green fluorescence protein
- the complete MG-725 genome was divided into eight fragments with overlap regions. These fragments were amplified from viral RNA and were assembled into pCMV vector, between two ribozymes, to generate pMG-725 plasmid according to the order of virus genome (Leader-N-P-M-F-HN-L-Trailer) and restriction sites (Fig. 1 F). F gene of MG-725 was modified by overlap PCR to obtain a lentogenic cleavage site identical to that of the LaSota strain (hereafter called Fmu). The Fmu gene replaced that of pMG-725 plasmid to obtain pMG-725/Fmu.
- the EGFP or mcherry fluorescent gene with gene start (GS) and gene end (GE) of MG-725 was amplified from pEGFP-C1 or pmCherry-N 1 (Clontech) and then cloned into pMG-725 and pMG-725/Fmu plasmids, between the P and M genes, to get pMG- 725/EGFP, pMG-725/Cherry, pMG-725/Fmu/EGFP, and pMG-725/Fmu/Cherry plasmids.
- the complete genome of the LaSota strain was divided into seven fragments. These seven fragments were amplified and assembled into pCMV to get pLaSota.
- the mcherry fluorescent gene with GS and GE of LaSota was inserted between the P and M genes of pLaSota to generate pLaSota/Cherry.
- the F and HN genes of pLaSota were replaced individually with those of pMG-725/Fmu to get pLaSota/M-Fmu, pLaSota/M-HN.
- Example 1 Validation of 4-plasmids and 2-plasmids systems on the EGFP mini- genome.
- the transfection media were replaced by 2 ml of MEM medium containing 10% FBS.
- Cells expressing EGFP were checked daily for 3 days after transfection.
- EGFP positive cells were enumerated in 10 different fields under the fluorescent microscope 2 days after transfection.
- To optimize the 4-plasmids system 1 10 5 BHK-21 cells were seeded on 24-well plates one day before transfection.
- a mixture of 0.5 ⁇ g pMini- genome, 0.1 ⁇ g pL and 0.4 ⁇ g of [pN and pP, with ratios ranging from 9:1 to 1 :9] was then transfected into cells. The number of cells expressing EGFP was determined under the fluorescent microscope two days after transfection.
- Example 2 Virus rescue with the 4-plasmids system.
- Example 3 Generation of the G-725/Fmu/EGFP strain with the 4-plasmids and the 2- plasmids systems.
- the total amount of the plasmids delivered to the cells was set at 2 and 3 ⁇ g with a ratio of 5:2:2: 1 [pGenome: pN: pP: pL] or 1 : 1 [pGenome: pNPL].
- fluorescence was checked under the microscope and cells and their supernatants were collected and used for virus amplification in eggs.
- RNAs were first digested with TURBO DNase enzyme (Ambion) to prevent DNA contamination.
- This optimized 4-plasmids system was then used to rescue 10 different viruses, three of which were expected to be velogenic (virulent), while the seven others were lentogenic (attenuated) (Table 1 ).
- This distinction is based on the amino acid motif found at the F protein cleavage site.
- the velogenic strains have five basic amino acids, while the lentogenic strains have two basic amino acids (Fig. 3). This difference makes the F protein of virulent strains more prone to be cleaved by various proteases present in various tissues and the virus is then activated to amplify whereas the F protein of attenuated strains is only cleaved in environments like the digestive and respiratory tracts or in vitro, in cell culture medium containing trypsin (13).
- Viruses were successfully rescued after confirmation by HA and qRT-PCR.
- the 2-plasmids system outperformed the 4-plasmids system in the replication of the EGFP mini-genome.
- the 2-plasmids system generates more viruses with lentogenic-like F protein cleavage sites.
- pMG-725/Fmu/EGFP plasmid containing the full genome of an attenuated green fluorescent recombinant virus was transfected into BHK-21 cells either with pN, pP and pL or pNPL. Based on the EGFP expression of transfected cells, the 2-plasmids system clearly outperformed the 4-plasmids system for the rescue of this lentogenic virus (Fig. 6A and B).
- Viruses were considered as successfully rescued after confirmation by HA and qRT-PCR. Viruses were not rescued.
- the condition for the rescue was 2 ⁇ g plasmids, one day after transfection.
- the condition for the rescue was 3 ⁇ g plasmids, 3 days after transfection. c Viruses were considered as successfully rescued after confirmation by HA and qRT-PCR. d Viruses were not rescued.
- plasmid including the full genome of PPR vaccine attenuated strain Nigeria 75/1 with a cassette expressing eGFP and flanked in 3' end by CMV promoter and ribozyme, and in 5' end by ribozyme and poly A tail (SEQ ID NO: 30);
- Transfection was perfomed with lipofectamin 3000 with a final quantity of 2.5 ⁇ g of plasmid in proportion 5:2:2:1 [pGenome: pN: pP: pL].
- Cells were put in contact with lipofectamin and plasmid (concentration following manufacturer's instruction) during 4h before removing lipofectamin mix and adding culture medium to cells. After several days, once cells reached confluence, they were put in contact with trypsin to detach them and transferred into 25cm 3 flasks with fresh medium. At confluence, they were transferred again in 75cm 3 flasks with fresh medium.
- Transfection method was identical as in 5.1 except that only two plasmids in 10:1 ratio were used :
- plasmid including the full genome of PPR vaccine strain Nigeria 75/1 with a cassette expressing eGFP and flanked in 3' end by CMV promoter and ribozyme, and in 5' end by ribozyme and poly A tail (SEQ ID N0:30);
- Fluorescent PPRV was obtained only once out of 21 attempts in the classical method based on 4-plasmids, whereas fluorescent PPRV was obtained twice out of 3 attempts with the new method using the 2-plasmids system according to the invention.
- Newcastle disease virus V4 strain Newcastle disease virus V4 strain. Molecular biology reports 36:1909-1914.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305272 | 2017-03-14 | ||
PCT/EP2018/054903 WO2018166793A1 (en) | 2017-03-14 | 2018-02-28 | Improved reverse genetics for single strand negative rna viruses |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3596204A1 true EP3596204A1 (en) | 2020-01-22 |
Family
ID=58707437
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18706537.0A Pending EP3596205A1 (en) | 2017-03-14 | 2018-02-28 | Ndv recombinant vaccine |
EP18706536.2A Pending EP3596204A1 (en) | 2017-03-14 | 2018-02-28 | Improved reverse genetics for single strand negative rna viruses |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18706537.0A Pending EP3596205A1 (en) | 2017-03-14 | 2018-02-28 | Ndv recombinant vaccine |
Country Status (2)
Country | Link |
---|---|
EP (2) | EP3596205A1 (en) |
WO (2) | WO2018166793A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114774373A (en) * | 2022-04-27 | 2022-07-22 | 北京市农林科学院 | Carrier pigeon Newcastle disease virus genetic engineering modified attenuated strain and preparation method and application thereof |
CN116479047A (en) * | 2023-04-24 | 2023-07-25 | 吉林农业大学 | Newcastle disease virus double-plasmid rescue system, construction method, identification method and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100955502B1 (en) * | 2007-11-30 | 2010-04-30 | 대한민국 | Peptide fragments specifically reactive with antibodies against highly pathogenic Newcastle disease virus and uses thereof |
MX346643B (en) * | 2010-11-18 | 2016-11-11 | Investig Aplicada S A De C V | Newcastle disease virus and the use thereof as a vaccine. |
EP2718445B1 (en) * | 2011-06-08 | 2023-08-09 | Vishwas Joshi | A two plasmid mammalian expression system for production of recombinant proteins and viruses |
CN104059942B (en) * | 2013-03-20 | 2016-12-28 | 湖北省农业科学院畜牧兽医研究所 | Avian pneumo-encephalitis virus heat-resisting live vaccine vectors system and application thereof |
-
2018
- 2018-02-28 EP EP18706537.0A patent/EP3596205A1/en active Pending
- 2018-02-28 WO PCT/EP2018/054903 patent/WO2018166793A1/en unknown
- 2018-02-28 EP EP18706536.2A patent/EP3596204A1/en active Pending
- 2018-02-28 WO PCT/EP2018/054904 patent/WO2018166794A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018166793A1 (en) | 2018-09-20 |
WO2018166794A1 (en) | 2018-09-20 |
EP3596205A1 (en) | 2020-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Krishnamurthy et al. | Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation | |
Biacchesi et al. | Recombinant human metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate | |
US9051584B2 (en) | Heat-resistant newcastle disease virus live vaccine vector system and use thereof | |
Liu et al. | Generation by reverse genetics of an effective attenuated Newcastle disease virus vaccine based on a prevalent highly virulent Chinese strain | |
Liu et al. | Two-plasmid system to increase the rescue efficiency of paramyxoviruses by reverse genetics: the example of rescuing Newcastle disease virus | |
US7244558B1 (en) | Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines | |
Yu et al. | Roles of the polymerase-associated protein genes in Newcastle disease virus virulence | |
Wang et al. | Development of a reverse genetics system based on RNA polymerase II for Newcastle disease virus genotype VII | |
Harty et al. | Vaccinia virus-free recovery of vesicular stomatitis virus | |
US8673315B2 (en) | Method for producing vaccinal viral strain of a virus of the reoviridae family | |
WO2007025431A1 (en) | Recombinant newcastle disease lasota attenuated vaccine strain expressing vp2 gene of infectious bursal disease virus | |
CN112458064A (en) | Gatasavir full-length infectious clone, replicon system, preparation and application thereof | |
EP3596204A1 (en) | Improved reverse genetics for single strand negative rna viruses | |
Parks et al. | Expression of a foreign gene by recombinant canine distemper virus recovered from cloned DNAs | |
Sun et al. | Generation and evaluation of a genetically attenuated Newcastle disease virus rGM-VIIm as a genotype-matched vaccine | |
Yunus et al. | Rescue of a bovine respiratory syncytial virus genomic RNA analog by bovine, human and ovine respiratory syncytial viruses confirms the “functional integrity” and “cross-recognition” of BRSV cis-acting elements by HRSV and ORSV | |
Wang et al. | Rapid development of an effective newcastle disease virus vaccine candidate by attenuation of a genotype VII velogenic isolate using a simple infectious cloning system | |
Liu et al. | Comparison of the efficiency of different Newcastle disease virus reverse genetics systems | |
CN112126629B (en) | Heat-resistant Newcastle disease virus mutant strain and preparation method and application thereof | |
CN113005100B (en) | Genetic modification method for changing heat stability of enveloped virus, recombinant virus and application thereof | |
Jiang et al. | Plasmids driven minigenome rescue system for Newcastle disease virus V4 strain | |
US20210275662A1 (en) | Method for rescuing and producing a virus in avian cells | |
JPWO2007007921A1 (en) | Segmented genome-type recombinant mononegavirus vector | |
Haas et al. | Reverse Genetics Systems for the De Novo Rescue of Diverse Members of Paramyxoviridae | |
Niyokwishimira et al. | Reverse genetics for Peste des petits ruminants virus: current status and lessons to learn from other non-segmented negative-sense RNA viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191011 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230221 |